Mendillo Jane L 4

What Happened Jane L. Mendillo, a director of Generate Biomedicines (GENB), made two reported acquisitions. On 2026-03-02 she purchased 1,500 common shares in an open-market purchase at $16.00 each for a total of $24,000. On 2026-02-26 she received a derivative award covering 29,561 shares (no cash paid), which appears to be an option-style grant.

Key Details

• Open-market purchase: 1,500 shares @ $16.00 on 2026-03-02 — total cost $24,000 (transaction code P).
• Award/grant: 29,561 shares (derivative) on 2026-02-26 @ $0.00 (transaction code A).
• Vesting note: The shares underlying the option award vest in full on February 19, 2027, subject to Ms. Mendillo’s continued service (Footnote F1).
• Shares owned after the transactions: not specified in the provided filing.
• Filing date: Form 4 filed 2026-03-02 (appears timely for both transactions).

Context The open-market purchase is a direct buy of common stock (often considered a clearer sign of an insider adding shares), while the award is a typical equity grant/option for service that vests in the future. There is no indication the award was exercised or that any shares were immediately sold. The filing was submitted on 2026-03-02 and shows no late-reporting flag.